查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1776217

鼻腔给药:市场洞察·竞争情形·市场预测 (～2032年)

Intranasal Drug Delivery - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预计鼻腔给药市场规模将从2024年的644.512亿美元成长至2032年的1042.4863亿美元，预测期内复合年增长率为6.24%。

此成长主要源自于慢性疾病盛行率的上升，包括神经系统疾病、呼吸系统疾病、严重过敏性疾病和眼科疾病。对快速起效、非侵入性给药方式的需求日益增长，也促进了市场扩张。尤其是鼻腔给药，其吸收迅速、给药便捷，有助于提高患者依从性和疗效。此外，各大公司加强研发投入与产品上市力度，加速了该领域的技术创新。这些发展推动了更有效率、更有针对性的鼻腔治疗方案的开发，使市场更具活力和竞争力。这些趋势为市场持续成长创造了有利环境，预计2025年至2032年间市场将强劲且稳定地扩张。

鼻腔给药市场动态：

根据世界卫生组织 (WHO) 2024年发布的数据，预计到2023年，全球将有约5,000万人患有癫痫，成为最常见的神经系统疾病之一。约80%的病例集中在中低收入国家，这些国家及时治疗的机会仍然有限。在这些地区，鼻腔给药是一种实用、快速起效且无需医疗监督的治疗方法，是一种有效的替代疗法。癫痫发病率的不断上升正在推动市场成长，鼻腔给药被用于治疗癫痫患者的急性发作。

同样，忧郁症仍然是一个全球性的健康问题。根据世界卫生组织估计，2023年全球将有2.8亿人患有忧郁症。鼻腔给药已成为治疗难治性忧郁症的有效方法，尤其是在门诊和急诊环境中，对快速缓解症状和便捷给药的需求日益增长。这促使对鼻腔给药解决方案的需求不断增长。

全球糖尿病负担也迅速增加。根据国际糖尿病联盟（2023年）的预测，预计2021年糖尿病患者人数将达到5.37亿，2030年将达到6.43亿，2045年将达到7.83亿。胰高血糖素等激素的创新鼻腔製剂提供了一种非侵入性、快速起效的注射疗法替代方案，并有助于控製糖尿病患者的急性低血糖，同时避免肝臟代谢。因此，糖尿病患者数量的增加正在推动鼻腔给药市场的成长。

全球糖尿病负担也迅速增加。根据国际糖尿病联盟 (IDF) 2023 年的数据，2021 年全球 20-79 岁成年人糖尿病患者人数为 5.37 亿，预计到 2030 年将增至 6.43 亿，到 2045 年将增至 7.83 亿。升糖素等激素的创新鼻腔製剂提供了一种非侵入性、快速起效的注射替代方案，避免了肝臟首过代谢，并有助于急性低血糖管理。因此，糖尿病患者的增加进一步推动了市场的成长。

慢性疼痛和偏头痛也影响着全球许多人。根据欧洲疼痛研究协会联合会 (2023) 的数据，到 2023 年，约有 1.5 亿欧洲人将遭受慢性疼痛的折磨。世界卫生组织估计，2021 年全球约有 31 亿人患有偏头痛和其他头痛疾病。用于治疗急性偏头痛发作的鼻腔给药药物因其快速起效且无需消化道，需求正在增加。

本报告研究了全球鼻腔给药市场，并提供了全面的概述、市场影响因素和机会分析、监管环境、市场规模趋势和预测、按细分市场、地区和主要国家/地区进行的详细分析、竞争格局以及主要公司的概况。

目录

第1章 鼻腔给药市场报告:简介

第2章 鼻腔给药市场摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 鼻腔给药市场:主要要素分析

  • 推动市场要素
    • 慢性病发生率上升
    • 对速效和非侵入性给药的需求不断增长
    • 研发活动增加以及疾病领域主要公司的产品发布
  • 市场限制与课题
    • 鼻腔给药的复杂性与局限性
    • 产品核准的严格监理要求
  • 市场机遇
    • 奈米製剂与个人化医疗的进展

第6章 鼻腔给药市场:波特的五力分析

第7章 鼻腔给药市场评估

  • 各剂型
    • 喷雾
    • 水滴·液体
    • 凝胶
    • 粉末
  • 容器别
    • 加压
    • 非加压
  • 各系统
    • 单剂量系统
    • 双剂量系统
    • 多剂量系统
  • 各用途
    • 呼吸疾病
    • 神经疾病
    • 感染疾病
    • 其他
  • 各流通管道
    • 医院药局
    • 线上药局
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 鼻腔给药市场:企业·产品简介

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • EMERGENT
  • UCB S.A.
  • GSK plc
  • Amphastar Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Hikma Pharmaceuticals PLC
  • Perrigo Company
  • ARS Pharmaceuticals Operations, Inc.
  • AstraZeneca
  • Therakind
  • AFT Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Currax Pharmaceuticals LLC
  • Impel Pharmaceuticals LLC
  • Endo, Inc.
  • Procter & Gamble
  • Teleflex Incorporated
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC

第9章 KOL的见解

第10章 计划方法

第11章 关于DelveInsight

第12章 免责声明·联络方式

Product Code: DIMDCL0492

Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to The growing prevalence of chronic diseases and increasing R&D activities and product launches by key players in the domain of intranasal drug delivery.

The intranasal drug delivery market was valued at USD 64,451.20 million in 2024, growing at a CAGR of 6.24% during the forecast period from 2025 to 2032 to reach USD 104,248.63 million by 2032. This growth is primarily driven by the rising prevalence of chronic diseases, including neurological, respiratory, severe allergic, and ophthalmic disorders. The increasing demand for rapid-onset, non-invasive drug administration methods is also contributing to market expansion, as intranasal delivery offers fast absorption and ease of use, key factors in enhancing patient compliance and therapeutic outcomes. Moreover, heightened R&D activities and a surge in product launches by key industry players are further accelerating innovation in the field. These advancements are creating a dynamic and competitive landscape, fostering the development of more efficient and targeted intranasal therapies. Together, these trends are shaping a favorable environment for the sustained growth of the intranasal drug delivery market, positioning it for robust and consistent expansion throughout the forecast period from 2025 to 2032.

Intranasal Drug Delivery Market Dynamics:

According to the World Health Organization (2024), in 2023, epilepsy affected approximately 50 million people worldwide, making it one of the most common neurological disorders. Notably, around 80% of these cases occurred in low- and middle-income countries, where access to timely treatment remains limited. In such settings, intranasal drug delivery provides a practical, fast-acting alternative that can be administered without medical supervision. Such growing cases of epilepsy are driving the market growth as intranasal drug delivery is used for the acute treatment of intermittent episodes of increased seizure activity in patients with epilepsy.

Similarly, depression remains a major global health concern. As per WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. Intranasal therapies emerged as effective treatments for treatment-resistant depression, offering rapid symptom relief and easy administration, especially in outpatient and emergency care environments thereby creating the demand for intranasal drug delivery solutions.

The global diabetes burden is also rising rapidly. According to the International Diabetes Federation (2023), in 2021, there were 537 million adults (aged 20-79) living with diabetes, a number projected to increase to 643 million by 2030 and 783 million by 2045. Innovative intranasal formulations of hormones like glucagon provide a non-invasive, fast-acting alternative to injectable therapies, helping manage acute hypoglycemia in diabetic patients while bypassing hepatic metabolism. Therefore, rising cases of diabetes are driving the growth of the intranasal drug delivery market.

Additionally, chronic pain and migraine continue to affect large populations worldwide. According to the European Pain Federation (2023), in 2023, approximately 150 million people in Europe suffered from chronic pain. Meanwhile, the WHO (2024), estimated that migraine and other headache disorders affected 3.1 billion people globally in 2021. The demand for intranasal drug delivery solutions is increasing due to rising cases of migraine as these devices manage acute migraine attacks, offering quick relief by bypassing the gastrointestinal tract.

According to NHS England (2023), approximately 5.4 million individuals received treatment for asthma in 2023, with around 160,000 new diagnoses recorded annually in the United Kingdom. This rising prevalence of asthma is a significant driver of growth in the intranasal drug delivery market. Intranasal delivery presents a promising approach for asthma management, offering advantages such as ease of administration, rapid onset of action, and the ability to bypass first-pass metabolism. These benefits not only improve patient compliance but also enhance therapeutic efficiency, further contributing to the growing adoption of intranasal drug delivery systems in the treatment of respiratory conditions like asthma.

Conditions like depression, epilepsy, chronic pain, diabetes, and respiratory disorders often require medications that are either rapidly metabolized by the liver or difficult to administer orally during acute episodes. Intranasal drug delivery offers key advantages in such cases, including rapid absorption, avoidance of first-pass hepatic metabolism, and reduced side effects due to the lower doses required. Therefore, the growing prevalence of chronic diseases such as neurological disorders, respiratory conditions, and diabetes is significantly driving the growth of the intranasal drug delivery market.

The intranasal drug delivery market is further propelled by ongoing product approvals and launches from key industry players, reinforcing innovation and expanding treatment options. For example, in February 2025, Lupin Limited announced it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution. This product is indicated for the symptomatic relief of rhinorrhea associated with both allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Similarly, in April 2024, Amneal Pharmaceuticals received U.S. FDA approval for its Over-the-counter (OTC) Naloxone Hydrochloride Nasal Spray, intended for the emergency treatment of opioid overdose. These developments not only underscore the growing adoption of intranasal formulations but also highlight the increasing focus on accessibility, patient convenience, and rapid therapeutic response key factors fueling the market's sustained growth.

However, the complexities and limitations associated with the intranasal drug administration and stringent regulatory requirements for product approval, among others are some of the key constraints that may limit the growth of the intranasal drug delivery market.

Intranasal Drug Delivery Market Segment Analysis:

Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the dosage form segment of the intranasal drug delivery market, the spray category is estimated to account for the largest market share in 2024. This robust growth is primarily driven by the increasing prevalence of respiratory diseases, severe allergic reactions, ophthalmic disorders, and neurological conditions, coupled with the multiple clinical and practical advantages offered by nasal sprays.

Nasal sprays are favored for their non-invasive, needle-free application, offering ease of administration and rapid onset of action are the factors that significantly enhance patient compliance and therapeutic efficiency. The nasal mucosa's highly vascularized and permeable surface enables efficient systemic absorption of drugs while bypassing the first-pass hepatic metabolism and avoiding gastrointestinal degradation. This leads to improved bioavailability, especially for drugs that are unstable or poorly absorbed through oral routes.

Moreover, nasal sprays are increasingly being utilized in the treatment of central nervous system (CNS) disorders. Their ability to deliver drugs via the olfactory and trigeminal nerve pathways allows for direct access to the brain, making them particularly effective in treating acute neurological conditions such as migraines, seizures, and opioid overdoses, where immediate therapeutic intervention is critical.

With the global burden of neurological diseases on the rise, leading pharmaceutical companies are intensifying their investments in research and development to introduce advanced intranasal spray formulations targeting these conditions. For example, in March 2023, Pfizer Inc. received FDA approval for ZAVZPRET(TM) (zavegepant), a CGRP receptor antagonist nasal spray indicated for the acute treatment of migraine, with or without aura, in adults. Similarly, in August 2023, Emergent BioSolutions launched NARCAN(R) Naloxone HCl Nasal Spray 4 mg, an over-the-counter (OTC) product designed for the emergency treatment of opioid overdose. These product innovations and regulatory milestones underscore the increasing clinical relevance of nasal sprays in both urgent care and chronic disease management. As such, the spray segment is poised for substantial expansion, driven by a convergence of therapeutic demand, technological advancement, and regulatory support.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of intranasal drug delivery across the globe.

North America is expected to dominate the overall intranasal drug delivery market:

North America is expected to hold the largest share of the intranasal drug delivery market in 2024, driven by several key factors. The region's dominance is primarily attributed to the rising prevalence of neurological, respiratory, and diabetes, which has created a growing demand for more effective and patient-friendly drug delivery solutions. Additionally, the increasing preference for rapid-onset therapies and the convenience of self-administration is significantly boosting the adoption of intranasal drug delivery systems across the region. Moreover, increase in regulatory approvals and new product launches by leading pharmaceutical companies with a strong pipeline of intranasal formulations, coupled with favorable healthcare infrastructure and awareness. Collectively, these factors are expected to sustain North America's leading position in the global market.

As per the data from the National Institute of Health (2023), in 2022, it was estimated that more than one in five adults were living with a mental illness (59.3 million) with 21 million people suffering from one major depressive disorder. Similarly, data from the Government of Canada (2023), in 2022, approximately 5 million people were suffering from mental disorders including major depressive disorders, anxiety, and seizures among others. Intranasal drug delivery devices with drugs are used for treatment-resistant depression and major depressive disorder with suicidal ideation.

According to the Centers for Disease Control and Prevention (2024), in 2022, approximately 2.9 million adults aged 18 and older in the U.S. reported having active epilepsy.

Additionally, data from the Anxiety & Depression Association of America (2022), revealed that 2 to 3% of individuals in the country experienced panic disorder, with women being twice as likely to be affected as men. Furthermore, generalized anxiety disorder (GAD) impacted around 6.8 million adults, or 3.1% of the U.S. population, underscoring the widespread burden of anxiety-related conditions.

The increasing incidence of such neurological and psychiatric disorders necessitates fast-acting, non-invasive treatment options, for which intranasal drug delivery offers a highly effective solution.

According to the Asthma and Allergy Foundation of America (2023), more than 27 million people in the United States were living with asthma in 2022, accounting for approximately 1 in every 12 individuals. Additionally, over 2 million adults aged 18 or older were affected by asthma. Data from the Allergy & Asthma Network (2023), further supported this, indicating that more than 26 million people, including 7% of adults and 6.5% of children, were living with asthma across the country.

Similarly, according to the Centers for Disease Control and Prevention (CDC, 2024), an estimated 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD). The data from the American Lung Association (2023), reported that 1.7 million individuals were diagnosed with COPD and other respiratory diseases, representing 4.6% of the U.S. population. The growing prevalence of asthma, COPD, and related respiratory conditions has led to a surging demand for intranasal drug delivery, which provides effective symptom relief and helps control disease progression.

The rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) is driving growth in the intranasal drug delivery market in the region, as patients seek fast-acting, non-invasive therapies to manage respiratory symptoms like nasal congestion and airway inflammation. Intranasal corticosteroids and decongestants provide targeted relief with fewer systemic side effects, enhancing patient compliance and treatment effectiveness.

In addition to disease prevalence, regulatory advancements and product innovations are further fueling market growth. For instance, in September 2024, AstraZeneca announced that FluMist(R), the only self-administered influenza vaccine, was approved in the U.S. This needle-free nasal spray can be self-administered by adults up to 49 years old or administered by a caregiver to individuals aged 2-17, marking a major step forward in patient-friendly vaccine delivery.

Intranasal Drug Delivery Market Key Players:

Some of the key market players operating in the intranasal drug delivery market include Pfizer Inc., Johnson & Johnson Services, Inc., EMERGENT, UCB S.A., GSK plc, Amphastar Pharmaceuticals, Inc., Neurelis, Inc., Hikma Pharmaceuticals PLC, Perrigo Company, ARS Pharmaceuticals Operations, Inc., AstraZeneca, Therakind, AFT Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Impel Pharmaceuticals LLC, Endo, Inc., Procter & Gamble, Teleflex Incorporated, Viatris, Inc., Amneal Pharmaceuticals LLC, and others.

Recent Developmental Activities in the Intranasal Drug Delivery Market:

  • In January 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for SPRAVATO(R) (esketamine) CIII nasal spray. This approval makes SPRAVATO(R) the first and only monotherapy specifically indicated for adults with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants.
  • In November 2024, Corxel Pharmaceuticals announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC) approved the New Drug Application (NDA) for varenicline solution nasal spray. This approval allowed the product to be marketed in China for the treatment of dry eye disease by increasing natural tear production, offering patients a novel, non-invasive therapeutic option.
  • In August 2024, ARS Pharmaceuticals received FDA approval for neffy(R) (epinephrine nasal spray), marking a groundbreaking advancement as the first and only needle-free epinephrine treatment for Type I allergic reactions, including life-threatening anaphylaxis. This approval represented a significant milestone in allergy care, offering patients and caregivers a rapid, effective, and more accessible alternative to traditional auto-injectors.
  • In January 2023, AstraZeneca announced the FDA approval of Airsupra (albuterol/budesonide), an as-needed inhaler for the treatment and prevention of bronchoconstriction and exacerbations in adults with asthma aged 18 years and older.

Key takeaways from the intranasal drug delivery market report study

  • Market size analysis for current intranasal drug delivery market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the intranasal drug delivery market.
  • Various opportunities available for the other competitors in the intranasal drug delivery market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current intranasal drug delivery market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for intranasal drug delivery market growth in the coming future?

Target audience who can benefit from this intranasal drug delivery market report study

  • Intranasal drug delivery product providers
  • Research organizations and consulting companies
  • Intranasal drug delivery-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in intranasal drug delivery
  • Various end-users who want to know more about the intranasal drug delivery market and the latest technological developments in the intranasal drug delivery market.

Frequently Asked Questions for the Intranasal Drug Delivery Market:

1. What is intranasal drug delivery?

  • Intranasal drug delivery is a method of administering medications through the nasal cavity for local or systemic effects. It offers rapid absorption due to the rich blood supply in the nasal mucosa and bypasses first-pass liver metabolism. This route is non-invasive, needle-free, and especially useful for emergency and CNS-related treatments.

2. What is the market for intranasal drug delivery?

  • The intranasal drug delivery market was valued at USD 64,451.20 million in 2024, growing at a CAGR of 6.24% during the forecast period from 2025 to 2032 to reach USD 104,248.63 million by 2032.

3. What are the drivers for the intranasal drug delivery market?

  • This growth is primarily driven by the rising prevalence of chronic diseases, including neurological, respiratory, severe allergic, and ophthalmic disorders. The increasing demand for rapid-onset, non-invasive drug administration methods is also contributing to market expansion, as intranasal delivery offers fast absorption and ease of use, key factors in enhancing patient compliance and therapeutic outcomes. Moreover, heightened R&D activities and a surge in product launches by key industry players are further accelerating innovation in the field. These advancements are creating a dynamic and competitive landscape, fostering the development of more efficient and targeted intranasal therapies. Together, these trends are shaping a favorable environment for the sustained growth of the intranasal drug delivery market, positioning it for robust and consistent expansion throughout the forecast period from 2025 to 2032.

4. Who are the key players operating in the intranasal drug delivery market?

  • Some of the key market players operating in the intranasal drug delivery market include Pfizer Inc., Johnson & Johnson Services, Inc., EMERGENT, UCB S.A., GSK plc, Amphastar Pharmaceuticals, Inc., Neurelis, Inc., Hikma Pharmaceuticals PLC, Perrigo Company, ARS Pharmaceuticals Operations, Inc., AstraZeneca, Therakind, AFT Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Impel Pharmaceuticals LLC, Endo, Inc., Procter & Gamble, Teleflex Incorporated, Viatris, Inc., Amneal Pharmaceuticals LLC, and others.

5. Which region has the highest share in the intranasal drug delivery market?

  • North America is expected to hold the largest share of the intranasal drug delivery market in 2024, driven by several key factors. The region's dominance is primarily attributed to the rising prevalence of neurological, respiratory, and diabetes, which has created a growing demand for more effective and patient-friendly drug delivery solutions. Additionally, the increasing preference for rapid-onset therapies and the convenience of self-administration is significantly boosting the adoption of intranasal drug delivery systems across the region. Moreover, increase in regulatory approvals and new product launches by leading pharmaceutical companies with a strong pipeline of intranasal formulations, coupled with favorable healthcare infrastructure and awareness. Collectively, these factors are expected to sustain North America's leading position in the global market.

Table of Contents

1. Intranasal Drug Delivery Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Intranasal Drug Delivery Market Executive Summary

  • 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1 The United States
  • 4.2 Europe
  • 4.3 Japan
  • 4.4 China

5. Intranasal Drug Delivery Market Key Factors Analysis

  • 5.1 Intranasal Drug Delivery Market Drivers
    • 5.1.1 The growing prevalence of chronic diseases
    • 5.1.2 Rising demand for rapid onset and non-invasive drug administration
    • 5.1.3 Increasing R&D activities and product launches by key players in the domain of intranasal drug delivery diseases
  • 5.2 Intranasal Drug Delivery Market Restraints and Challenges
    • 5.2.1 Complexities and limitations associated with the intranasal drug administration
    • 5.2.2 Stringent regulatory requirements for product approval
  • 5.3 Intranasal Drug Delivery Market Opportunity
    • 5.3.1 Advancements in nano-formulations and personalized medicine

6. Intranasal Drug Delivery Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Intranasal Drug Delivery Market Assessment

  • 7.1 By Dosage Form
    • 7.1.1 Spray
    • 7.1.2 Drops and Liquids
    • 7.1.3 Gels
    • 7.1.4 Powders
  • 7.2 By Container
    • 7.2.1 Pressurized
    • 7.2.2 Non-pressurized
  • 7.3 By System
    • 7.3.1 Unit-dose Systems
    • 7.3.2 Bi-Dose Systems
    • 7.3.3 Multi-dose Systems
  • 7.4 By Application
    • 7.4.1 Respiratory Disorders
    • 7.4.2 Neurological Disorders
    • 7.4.3 Infectious Diseases
    • 7.4.4 Others
  • 7.5 By Distribution Channel
    • 7.5.1 Hospital & Retail Pharmacies
    • 7.5.2 Online Pharmacies
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.1.2 Canada Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.1.3 Mexico Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.2 Europe
      • 7.6.2.1 France Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.2 Germany Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.3 United Kingdom Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.4 Italy Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.5 Spain Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.6 Rest of Europe Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.2 Japan Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.3 India Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.4 Australia Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.5 South Korea Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.6 Rest of Asia-Pacific Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 Middle East Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.4.2 Africa Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.4.3 South America Intranasal Drug Delivery Market Size In USD Million (2022-2032)

8. Intranasal Drug Delivery Market Company and Product Profiles

  • 8.1 Pfizer Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Company Snapshot
    • 8.1.3 Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5 Entropy
  • 8.2 Johnson & Johnson Services, Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Company Snapshot
    • 8.2.3 Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5 Entropy
  • 8.3 EMERGENT
    • 8.3.1 Company Overview
    • 8.3.2 Company Snapshot
    • 8.3.3 Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5 Entropy
  • 8.4 UCB S.A.
    • 8.4.1 Company Overview
    • 8.4.2 Company Snapshot
    • 8.4.3 Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5 Entropy
  • 8.5 GSK plc
    • 8.5.1 Company Overview
    • 8.5.2 Company Snapshot
    • 8.5.3 Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5 Entropy
  • 8.6 Amphastar Pharmaceuticals, Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Company Snapshot
    • 8.6.3 Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5 Entropy
  • 8.7 Neurelis, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Company Snapshot
    • 8.7.3 Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5 Entropy
  • 8.8 Hikma Pharmaceuticals PLC
    • 8.8.1 Company Overview
    • 8.8.2 Company Snapshot
    • 8.8.3 Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5 Entropy
  • 8.9 Perrigo Company
    • 8.9.1 Company Overview
    • 8.9.2 Company Snapshot
    • 8.9.3 Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5 Entropy
  • 8.10. ARS Pharmaceuticals Operations, Inc.
    • 8.10.1 Company Overview
    • 8.10.2 Company Snapshot
    • 8.10.3 Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5 Entropy
  • 8.11 AstraZeneca
    • 8.11.1 Company Overview
    • 8.11.2 Company Snapshot
    • 8.11.3 Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5 Entropy
  • 8.12. Therakind
    • 8.12.1 Company Overview
    • 8.12.2 Company Snapshot
    • 8.12.3 Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5 Entropy
  • 8.13. AFT Pharmaceuticals
    • 8.13.1 Company Overview
    • 8.13.2 Company Snapshot
    • 8.13.3 Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5 Entropy
  • 8.14. Teva Pharmaceutical Industries Ltd.
    • 8.14.1 Company Overview
    • 8.14.2 Company Snapshot
    • 8.14.3 Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5 Entropy
  • 8.15 Currax Pharmaceuticals LLC
    • 8.15.1 Company Overview
    • 8.15.2 Company Snapshot
    • 8.15.3 Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5 Entropy
  • 8.16 Impel Pharmaceuticals LLC
    • 8.16.1 Company Overview
    • 8.16.2 Company Snapshot
    • 8.16.3 Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5 Entropy
  • 8.17. Endo, Inc.
    • 8.17.1 Company Overview
    • 8.17.2 Company Snapshot
    • 8.17.3 Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5 Entropy
  • 8.18. Procter & Gamble
    • 8.18.1 Company Overview
    • 8.18.2 Company Snapshot
    • 8.18.3 Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5 Entropy
  • 8.19. Teleflex Incorporated
    • 8.19.1 Company Overview
    • 8.19.2 Company Snapshot
    • 8.19.3 Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5 Entropy
  • 8.20. Viatris Inc.
    • 8.20.1 Company Overview
    • 8.20.2 Company Snapshot
    • 8.20.3 Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5 Entropy
  • 8.21. Amneal Pharmaceuticals LLC
    • 8.21.1 Company Overview
    • 8.21.2 Company Snapshot
    • 8.21.3 Financial Overview
    • 8.21.4 Product Listing
    • 8.21.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Intranasal Drug Delivery Market in Global (2022-2032)
  • Table 3: Intranasal Drug Delivery Market in Global by Dosage Form (2022-2032)
  • Table 4: Intranasal Drug Delivery Market in Global by Container (2022-2032)
  • Table 5: Intranasal Drug Delivery Market in Global by System (2022-2032)
  • Table 6: Intranasal Drug Delivery Market in Global by Application (2022-2032)
  • Table 7: Intranasal Drug Delivery Market in Global by Distribution Channel (2022-2032)
  • Table 8: Intranasal Drug Delivery Market in Global by Geography (2022-2032)
  • Table 9: Intranasal Drug Delivery Market in North America (2022-2032)
  • Table 10: Intranasal Drug Delivery Market in the United States (2022-2032)
  • Table 11: Intranasal Drug Delivery Market in Canada (2022-2032)
  • Table 12: Intranasal Drug Delivery Market in Mexico (2022-2032)
  • Table 13: Intranasal Drug Delivery Market in Europe (2022-2032)
  • Table 14: Intranasal Drug Delivery Market in France (2022-2032)
  • Table 15: Intranasal Drug Delivery Market in Germany (2022-2032)
  • Table 16: Intranasal Drug Delivery Market in United Kingdom (2022-2032)
  • Table 17: Intranasal Drug Delivery Market in Italy (2022-2032)
  • Table 18: Intranasal Drug Delivery Market in Spain (2022-2032)
  • Table 19: Intranasal Drug Delivery Market in the Rest of Europe (2022-2032)
  • Table 20: Intranasal Drug Delivery Market in Asia-Pacific (2022-2032)
  • Table 21: Intranasal Drug Delivery Market in China (2022-2032)
  • Table 22: Intranasal Drug Delivery Market in Japan (2022-2032)
  • Table 23: Intranasal Drug Delivery Market in India (2022-2032)
  • Table 24: Intranasal Drug Delivery Market in Australia (2022-2032)
  • Table 25: Intranasal Drug Delivery Market in South Korea (2022-2032)
  • Table 26: Intranasal Drug Delivery Market in Rest of Asia-Pacific (2022-2032)
  • Table 27: Intranasal Drug Delivery Market in the Rest of the World (2022-2032)
  • Table 28: Intranasal Drug Delivery Market in the Middle East (2022-2032)
  • Table 29: Intranasal Drug Delivery Market in Africa (2022-2032)
  • Table 30: Intranasal Drug Delivery Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Intranasal Drug Delivery Market in Global (2022-2032)
  • Figure 3: Intranasal Drug Delivery Market in Global by Dosage Form (2022-2032)
  • Figure 4: Intranasal Drug Delivery Market in Global by Container (2022-2032)
  • Figure 5: Intranasal Drug Delivery Market in Global by System (2022-2032)
  • Figure 6: Intranasal Drug Delivery Market in Global by Application (2022-2032)
  • Figure 7: Intranasal Drug Delivery Market in Global by Distribution Channel (2022-2032)
  • Figure 8: Intranasal Drug Delivery Market in Global by Geography (2022-2032)
  • Figure 9: Intranasal Drug Delivery Market in North America (2022-2032)
  • Figure 10: Intranasal Drug Delivery Market in the United States (2022-2032)
  • Figure 11: Intranasal Drug Delivery Market in Canada (2022-2032)
  • Figure 12: Intranasal Drug Delivery Market in Mexico (2022-2032)
  • Figure 13: Intranasal Drug Delivery Market in Europe (2022-2032)
  • Figure 14: Intranasal Drug Delivery Market in France (2022-2032)
  • Figure 15: Intranasal Drug Delivery Market in Germany (2022-2032)
  • Figure 16: Intranasal Drug Delivery Market in United Kingdom (2022-2032)
  • Figure 17: Intranasal Drug Delivery Market in Italy (2022-2032)
  • Figure 18: Intranasal Drug Delivery Market in Spain (2022-2032)
  • Figure 19: Intranasal Drug Delivery Market in the Rest of Europe (2022-2032)
  • Figure 20: Intranasal Drug Delivery Market in Asia-Pacific (2022-2032)
  • Figure 21: Intranasal Drug Delivery Market in China (2022-2032)
  • Figure 22: Intranasal Drug Delivery Market in Japan (2022-2032)
  • Figure 23: Intranasal Drug Delivery Market in India (2022-2032)
  • Figure 24: Intranasal Drug Delivery Market in Australia (2022-2032)
  • Figure 25: Intranasal Drug Delivery Market in South Korea (2022-2032)
  • Figure 26: Intranasal Drug Delivery Market in Rest of Asia-Pacific (2022-2032)
  • Figure 27: Intranasal Drug Delivery Market in the Rest of the World (2022-2032)
  • Figure 28: Intranasal Drug Delivery Market in the Middle East (2022-2032)
  • Figure 29: Intranasal Drug Delivery Market in Africa (2022-2032)
  • Figure 30: Intranasal Drug Delivery Market in South America (2022-2032)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis